CIRAANO: Multimodal exploration of theater actors, memory athletes, and patients with various memory pathologies: evaluation of mnesic strategies and their cerebral substrates, and contribution to the treatment of memory pathologies.

Trial details

Who runs it

Institut National De La Sante Et De La Recherche Medicale

Trial code

EU 2025-523264-21-00

Record updated

2026. január 23.

Original description

[Part 2] to evaluate, in different categories of patients with memory disorders of various origins, the preservation or alteration of memory-related brain networks, associated with different types of memory strategies identified in memory experts.Read full original descriptionShow less

CIRAANO: Multimodal exploration (including radiopharmaceuticals Amyvid® and Tauvid®) of theater actors, memory athletes, and patients with various memory pathologies: evaluation of mnesic strategies and their cerebral substrates, and contribution to the treatment of memory pathologies.

[Part 2] to evaluate, in different categories of patients with memory disorders of various origins, the preservation or alteration of memory-related brain networks, associated with different types of memory strategies identified in memory experts.

Inclusion: [all participants] Minimum education level of 7 years (at least equivalent to the French Certificat d’Études Primaires (CEP)); [HC] Aged 18 or older; [HC] Neuropsychological performance within the normal range for age and education level on all inclusion battery tests (±1.65 standard deviation); [HC] Be considered capable of complying with the protocol according to the investigator's judgment; [ATHL] Aged 18 or older; [ATHL] Must have participated in a memory competition—international, European, or national level; [ATHL] Be considered capable of complying with the protocol according to the investigator's judgment; [SCD] Aged 60 or older; [SCD] Recruited from memory clinics; [SCD] Must meet recognized criteria for subjective cognitive decline in the context of the preclinical stage of Alzheimer’s disease; [MCI-AD] Aged 60 or older; [all participants] Native French speaker and educated in French; [MCI-AD] Recruited from memory clinics; [MCI-AD] Must meet current recognized clinical criteria for mild cognitive impairment due to Alzheimer’s disease; [D-AD] Aged 60 years or older; [D-AD] Recruited from memory clinics; [D-AD] Meeting current and recognized clinical criteria for major neurocognitive disorder due to probable Alzheimer’s disease; [LBD] Aged 60 years or older; [LBD] Recruited from memory clinics; [LBD] Meeting current and recognized clinical criteria for probable Lewy body dementia or probable prodromal Lewy body dementia (mild cognitive impairment with Lewy bodies); [svPPA] Aged 50 years or older; [svPPA] Recruited from memory clinics; [all participants] Affiliated with a French social security scheme or beneficiary of such a scheme; [svPPA] Meeting current and recognized clinical criteria for semantic dementia; [AUD] Aged 18 years or older; [AUD] Recruited from an addiction treatment service; [AUD] Undergoing treatment primarily for an alcohol use disorder at the time of inclusion; [AUD] Detoxified, with withdrawal symptoms resolved (Cushman score <3, Cushman et al., 1985) and benzodiazepines discontinued at the time of inclusion; [AUD] Abstinent from all psychoactive substances (except tobacco and prescribed medication) at the time of inclusion; [AMN] Aged 18 years or older; [AMN] Recruited from hospital services or residential facilities housing patients with non-degenerative amnesic syndromes; [AMN] Presenting with major cognitive impairment : Characterized primarily by severe episodic memory deficits (anterograde amnesia), possibly associated with retrograde amnesia and/or other impairments ; Leading to significant impacts on daily functioning and reduced autonomy ; Persistent and stable over time; [NARCO] Aged 18 years or older; [all participants] Willingness to undergo several days of assessments; [NARCO] - Diagnosed with type 1 narcolepsy according to the 3rd edition of the International Classification of Sleep Disorders (ICSD-3), which includes daytime sleepiness persisting for more than 3 months, and either : Presence of cataplexy, mean sleep latency <8 minutes on the Multiple Sleep Latency Test (MSLT), and at least two REM sleep onsets (on MSLT and/or overnight polysomnography) ; Or cerebrospinal fluid hypocretin level <110 pg/mL; [Informant] Aged 18 years or older; [Informant] Spending at least one day per week with a relative included in one of the patient groups; [all participants] Adherence to lifestyle considerations; [all participants] Signed informed consent to participate in the study; [ACT] Aged 18 or older; [ACT] Must have performed in at least one theatre play in the last three years; [ACT] Must be or have been a professional actor, either freelance or permanent (e.g., in a theatre company or at the Comédie-Française) for at least 5 years.

Exclusion: [MCI-AD] Use of Alzheimer’s disease medications (including but not limited to donepezil, rivastigmine, galantamine, and memantine) at non-stabilized doses within 8 weeks prior to the inclusion visit; [D-AD, LBD & svPPA] Use of Alzheimer’s disease medications (including but not limited to donepezil, rivastigmine, galantamine, and memantine) and/or L-DOPA for LBD patients, at non-stabilized doses within 8 weeks prior to the inclusion visit; [all participants except informants] Chronic use of medications that affect cognition and/or may interfere with cognitive or imaging assessments (including non-tricyclic antidepressants, anticonvulsants such as lamotrigine, pregabalin, levetiracetam ; atypical antipsychotics; short-/intermediate-acting benzodiazepines such as alprazolam, lorazepam, oxazepam, temazepam; and sedative antihistamines), if doses were not stabilized within the 6 weeks prior to inclusion (except for changes due to withdrawal treatment in AUD patients); [all participants except informants] Participation in a clinical study involving exposure to ionizing radiation within the year prior to inclusion; [all participants except informants] Current use of long-acting benzodiazepines, typical antipsychotics, tricyclic antidepressants, or first-generation antihistamines at the time of inclusion (unless related to withdrawal treatment in AUD patients), with discontinuation of such medication less than 3 months prior to inclusion; [ACT & ATHL] Use of Alzheimer’s disease medications (including but not limited to donepezil, rivastigmine, galantamine, and memantine) at non-stabilized doses within 8 weeks prior to the inclusion visit; [D-AD, LBD & svPPA] Absence of a caregiver or informant (i.e., a trusted person or relative who will be present from inclusion through the assessments, for patients with major cognitive impairment); [AUD & AMN] Evidence suggesting a probable neurodegenerative disorder (e.g., impairment in instrumental cognitive functions); [all participants except informants] Known hypersensitivity to Amyvid® or Tauvid®; [all participants except informants] History of neurological or neurosurgical conditions that could significantly affect cognitive function and/or neuroimaging (e.g., head trauma with loss of consciousness >30 minutes, stroke, multiple sclerosis, insulin coma); [all participants except informants] Schizophrenia, psychotic disorders, or bipolar disorders (according to DSM-5 criteria); [all participants except informants] Presence of untreated chronic or acute illnesses (respiratory, cardiovascular, gastrointestinal, renal, metabolic, hematologic, endocrine, or infectious); [all participants except informants] Pregnant or breastfeeding women; [all participants except informants] Presence of contraindications to MRI (e.g., claustrophobia, ferromagnetic objects in the body) or to Amyvid® and Tauvid® PET scans; [SCD] Presence of depressive symptoms (MADRS score > 34, threshold for severe depression); [MCI-AD] Presence of depressive symptoms (MADRS score > 34, threshold for severe depression); [D-AD, LBD & svPPA] Presence of depressive symptoms (MADRS score > 34, threshold for severe depression); [D-AD, LBD & svPPA] Inability to understand instructions; [AUD & AMN] Presence of depressive symptoms (MADRS score > 34, threshold for severe depression); [NARCO] Presence of depressive symptoms (MADRS score > 34, threshold for severe depression); [all participants except informants] Current participation in a clinical trial and/or other research involving human participants (RIPH) if it includes imaging examinations using radiotracers; [all participants except informants] Having a score suggesting an alcohol dependence (>9) on the FACE questionnaire (except for AUD patients); [all participants except informants] Physical, behavioral, or geographical limitations preventing participation in the study; [all participants except informants] Refusal to cooperate during assessments; [HC] Current or recent (within the last 5 years) theater practice; [HC] Presence of depressive symptoms (MADRS score > 19, threshold for moderate depression); [ACT & ATHL] Presence of depressive symptoms (MADRS score > 19, threshold for moderate depression).

EU CTIS 2025-523264-21-00